News

Logo for the Child and Adolescent TB Working Group
1 Sep 2018

As of September 2018, the Child and Adolescent TB Working Group has their own logo.

 

GLI launches its Guide to TB Specimen Referral Systems and Integrated Networks
13 Oct 2017

Efficient specimen referral systems contribute to optimal and timely access to TB diagnostic and treatment services. This guide provides practical information that will help developing and improving the efficiency of the specimen referral systems by establishing integrated solutions.

Targeting TB programme and laboratory managers, as well as other key stakeholders across various disease programmes, this guide presents a stepwise approach that aims at facilitating the planning and coordination of specimen referral systems, and also provides TB-specific considerations for collection, storage, packaging and transport of specimens.

Joint FIND and NDWG symposium
11 Oct 2017

11 October 2017, 13:00 - 17:00
Expo Guadalajara Convention Centre, Guadalajara, Mexico

This year, FIND and the New Diagnostics Working Group (NDWG) joined in convening partners and members at a symposium which was held on 11 October back-to-back with the 48th Union World Conference on Lung Health.

During the symposium, we provided an overview of the most recent advances in the global TB diagnostics pipeline and reviewed progress made in various areas to address diagnostic needs towards ending the TB epidemic. Sessions focused on the use of next-generation sequencing for surveillance, diagnosis and patient management, and on the development of new tests for latent TB infection to support TB elimination.

The event also involved a round table discussion around the challenges in molecular testing roll-out on a programmatic level. Panelists considered how the interpretation of genetic mutations can guide clinical decision for treatment and shared different perspectives about the prospects of scaling up molecular approaches in different settings.

Agenda

Presentations

Upgrading status of sub group to Working Group
1 Oct 2017

Stop TB Partnership is pleased to announce Working Group status of the Childhood TB subgroup, PPM sub group (formerly part of the DOTS expansion Working Group which is no longer functional) and the End TB Transmission Initiative (formerly TB Infection control subgroup). The Executive Committee have approved the request from the three groups and henceforth will be known as the Child and Adolescent TB Working Group, Public-Private Mix Working Group and the End TB Transmission Initiative Working Group.

GLI core group elects four new members
1 Sep 2017

The GLI core group is happy to announce the election of four new members for the 2017-2018 term: Petra de Haas, Christy Hanson, Daniel Orozco and Kaiser Shen. Petra de Haas is a Laboratory Advisor at the KNCV Tuberculosis Foundation. Dr Christy Hanson is a Senior Programme Officer on the TB Delivery Team at the Bill & Melinda Gates Foundation. Daniel Orozco is the Director of Laboratory Services at Partners in Health. Kaiser Shen is a TB Laboratory and Diagnostic Network Advisor at the United States Agency for International Development. For the complete membership of the GLI core group, click here.

The core group would like to deeply thank the members that have completed their terms - Dr Maarten van Cleeff and Amy Piatek - for their years of contributions to the group.

The seventh Core Group (CG) meeting of the Global Drug-resistant TB Initiative (GDI)
9 Jun 2017

The seventh Core Group (CG) meeting of the Global Drug-resistant TB Initiative (GDI) took place in Geneva, Switzerland on 9 June 2017.

The objectives of the meeting were:

  • To follow up on recommendations made and action points agreed upon during previous CG meetings and monthly teleconferences;
  • To update the GDI on the upcoming global events and recent WHO policy or other technical developments;
  • To discuss progress in scale up of MDR-TB services and care based on reports from regional initiatives and partner organizations;
  • To review and discuss progress in the work of GDI Task Forces;
  • To discuss GDI objectives and plan activities for the second half of 2017.

The report of the meeting and action points were compiled by the secretariat, approved by the core group and shared as a public document on the GDI website.

All meeting documents can be found at the " Meetings" tab."

Seventh core group meeting of the Global Drug-Resistant TB Initiative in Geneva, Switzerland

FDA approved Xpert MTB/RIF for simultaneous detection of tuberculosis and rifampicin resistance
19 Apr 2017

The U.S. Food and Drug Administration (FDA) recently allowed marketing of the Xpert MTB/RIF assay, the first FDA-reviewed test that can simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria contain genetic markers that make them resistant to rifampicin, one of the most used first-line drugs for the treatment of TB.

The FDA reviewed the Xpert MTB/RIF assay through the de novo classification process, a regulatory pathway for some low- to moderate-risk medical devices that are not substantially equivalent to an already legally marketed device. In support of the de novo petition the manufacturer submitted data that included an assessment of the test’s accuracy in identifying the TB bacteria and the rifampicin-resistant strains as compared to validated test methods.

FDA news release

New Diagnostics Working Group Annual Meeting
26 Oct 2016

Wednesday, 26 October 2016, 9:00 - 12:30
Arena and Convention Centre, Liverpool, UK

The NDWG convened its Annual Meeting on 26 October 2016 at the 47th Union World Conference on Lung Health in Liverpool, UK.

NDWG Task Force members and partners reviewed progress in various areas of diagnostics R&D to support the targets of the End TB strategy and the Global Plan to End TB. Presentations covered newer understanding of LTBI diagnosis, as well as advanced drafts of the TPP for a test of progression of incipient TB and the Framework for evaluation of novel LTBI tests; the perspectives of next generation sequencing for detection of drug resistance in high TB burden countries; and a recent overview of the biomarker pipeline for TB detection at the point-of-care level, including for paediatric TB.

The presentations and audio are now available on the NDWG website as follows:

  • Agenda
  • Session I - Supporting TB elimination: Advances towards delivering new diagnostics for latent tuberculosis infection
  • Session II - Next Generation Sequencing for improved management of patients with drug resistant TB
  • Session III - Advancing biomarker discovery for TB point-of-care tests
The sixth Core Group (CG) meeting of the Global Drug-resistant TB Initiative (GDI).
23 Oct 2016

The sixth Core Group (CG) meeting of the Global Drug-resistant TB Initiative (GDI) took place in Liverpool, UK on 23 October 2016. All members (bar 1) of the CG, attended the meeting, along with observers from the Global Laboratory Initiative (GLI), Global TB Drugs Facility (GDF), Global Fund (GF) and the GDI Task Forces.

The objectives of the meeting were:

  • To follow up on recommendations made and action points agreed upon during 5th GDI CG meeting in July 2016, and subsequent monthly teleconferences;
  • To discuss donor perspectives in the current MDR-TB landscape;
  • To provide an update on progress in scale up of MDR-TB services and care;
  • To provide an update on the progress of the respective GDI Task Forces; and
  • To update group on the civil society and advocacy related partner activities.

The participants were briefed about the activities of the GDI Secretariat since the fifth CG meeting held in July 2016. Chairs of regional GLC presented on the MDR-TB scale-up in their respective regions. This was followed by the respective GDI Task Forces presenting their progress and the activities in their respective areas to the GDI CG. The report of the meeting and action points were compiled by the secretariat, approved by the core group and shared as a public document on the GDI website.

All meeting documents can be found at the " Meetings" tab."

Sixth core group meeting of the Global Drug-Resistant TB Initiative in Liverpool, UK

GLI core group collaborates with WHO on development of Framework of indicators and targets for laboratory strengthening under the End TB Strategy
18 Oct 2016

18 October 2016- The End TB Strategy calls for the early diagnosis of TB including universal drug-susceptibility testing (DST), and a prerequisite for any national TB programme to reach this goal is a quality-assured laboratory network equipped with rapid diagnostics. The newly published WHO Framework of indicators and targets for laboratory strengthening under the End TB Strategy, developed in collaboration with a team from the GLI core group, serves as a guide for all countries developing plans for laboratory strengthening during 2016-2025.

The 12 core indicators under the Framework measure programmes’ capacity to detect TB accurately and rapidly using new diagnostics, provide universal DST, and ensure the quality of testing. These indicators will be monitored globally by WHO as countries progress towards reaching the targets. The Framework also provides methods for calculating country-specific targets for the numbers of tests and facilities needed for each of the main diagnostic technologies. Given advancements in diagnostic technologies and the need for country-specific targets that consider epidemiology and issues of patient access, the previous global targets that were based on numbers of facilities relative to the general population (1 microscopy center per 100,000 population, 1 culture facility per 5 million population, etc.) are no longer recommended.

The Framework is available online at www.who.int/tb/publications/labindicators